A Phase 3 Multicenter, Randomized, Double-Blind and Placebo-Controlled Study, and Open Study of KW-0761 in Patients With HTLV-1 Associated Myelopathy (HAM)
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 12 Jul 2019
Price : $35 *
At a glance
- Drugs Mogamulizumab (Primary)
- Indications Spinal cord disorders
- Focus Therapeutic Use
- Sponsors Kyowa Hakko Kirin
- 23 May 2018 Planned End Date changed from 1 May 2019 to 1 Dec 2020.
- 23 May 2018 Status changed from recruiting to active, no longer recruiting.
- 21 Jun 2017 New trial record